Ivergalen (Ivermectin)

Ivergalen is an antiparasitic medication used to manage infections caused by nematodes and ectoparasites.

• Onchocerciasis (river blindness): reduces microfilarial load and helps prevent ocular and skin disease.
• Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection.
• Scabies: eradicates Sarcoptes scabiei mites, relieving itching and skin lesions.
• Lice infestations: kills Pediculus humanus capitis and Pediculus humanus corporis, controlling spread.
• Other intestinal helminth infections: clears a variety of nematode species from the gastrointestinal tract.

• Ivermectin binds selectively to glutamate‑gated chloride channels in invertebrate nerve and muscle cells, increasing chloride ion influx. This hyperpolarizes the cell membrane, leading to paralysis and death of the parasite while having minimal effect on mammalian cells because these channels are absent in humans.

Ivergalen may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Dizziness: occasional light‑headedness.
• Abdominal pain: cramping or discomfort.
• Diarrhea: loose stools.
• Pruritus: itching of the skin.
• Headache: mild tension‑type pain.

Serious or Rare Side Effects

• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Hepatotoxicity: elevated liver enzymes or jaundice.
• Neurologic effects: seizures, ataxia or altered consciousness.
• Anaphylaxis: acute allergic response requiring emergency care.
• Vision changes: blurred vision or optic neuritis.
• Cardiac arrhythmias: rare conduction abnormalities.

Before prescribing Ivergalen, clinicians should consider several safety measures.

• Assess contraindications: avoid use in patients with known hypersensitivity to ivermectin.
• Monitor liver function: evaluate hepatic status in patients with pre‑existing liver disease.
• Caution with Loa loa infection: high microfilarial loads can precipitate severe reactions.
• Review concomitant medications: check for drugs that affect CYP3A4 or P‑glycoprotein pathways.
• Educate patients: advise on potential side effects and the importance of adherence.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivergalen can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivermectin plasma levels.
• P‑glycoprotein inhibitors (e.g., verapamil, quinidine): can raise systemic exposure.
• Concurrent neurotoxic agents (e.g., albendazole in high doses): risk of additive neurologic effects.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, monitor INR.
• Macrolide antibiotics (e.g., erythromycin): modest increase in ivermectin concentrations.
• Statins metabolized by CYP3A4: observe for muscle toxicity.